hahah ... good one. from what I have heard its super hot. I have...

hahah ... good one. from what I have heard its super hot. I have certainly missed out but will look to buy on market if it doesn open up 40-80%. slow, long term one this one with applications beyond HIV testing . See this particular section from the prospectus - not saying they have a test for corona but recent press release and this section may mean they might look into it in the future if this thing becomes huge.

https://www.theguardian.com/world/2020/mar/04/bill-and-melinda-gates-fund-study-into-finding-coronavirus-cure

https://www.vox.com/recode/2020/3/10/21173864/mark-zuckerberg-bill-gates-coronavirus-billionaire-philanthropy

3.4.1. ACUTE RESPIRATORYINFECTIONSDifferentiating between viral and bacterialupper respiratory infections is consideredto be a critical test in the battle to addressthe over prescription of antibiotics,and the resulting increase in antibioticresistance in the general population.

A 2019 report from the US CDC on“Antibiotic resistance threats in the UnitedStates” points out that “a test that candifferentiate bacterial, viral, or fungalinfection from other causes of symptoms,and which can be used across healthcaresettings (inpatient and outpatient),can significantly improve appropriateantibiotic use and reduce unnecessaryantibiotic use”.12Governments are also increasingawareness of AMR with changes inpolicy, R&D incentives and strategiesto scale up uptake of diagnostic use.For example, the UK in 2019 publishedits 5-year national action plan on“Tackling antimicrobial resistance 2019–2024” in which the development of noveldiagnostics and linking prescription ofantibiotics to diagnosis are two of thekey recommendations.13Atomo’s participation in the AMR rapidtest market is by way of its supplyof Pascal devices used by Lumos tocommercialise its FebriDx AMR screeningtest. FebriDX screening test detects 2biomarkers (MxA and CRP).Neither CRP nor MxA alone is sensitive orspecific enough to differentiate viral frombacterial infections. By combining a markerof bacterial infection, CRP, and a markerof viral infection, MxA, the dual biomarkertechnology of FebriDx improves thesensitivity and specificity of both markers